InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,718.57
(
0.28%
)
US TECH 100
19,312.80
(
0.08%
)
Dow Jones
42,124.65
(
0.15%
)
Brent Oil
74.11
(
0.51%
)
Bitcoin
63,268.89
(
-0.09%
)
Post# of 165
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

gfp927z

Send PM Follow Ignore
Followers 87
Posts 33439
Boards Moderated 87
Alias Born 03/22/2005

gfp927z

Re: CHM_760 post# 17

Monday, 01/19/2015 11:59:54 AM

Monday, January 19, 2015 11:59:54 AM

Post# of 165
CHM, Here are the Phase 2 presentation slides from 2012 (Polymedix). They used 3 dose levels of Brilacidin (PMX-30063), see slide 8, and dosed for 5 days (7 days for Daptomycin/Cubicin), then evaluated efficacy out to day 28. This is the type of complete data I'd like to see made available for Cellceutix's Phase 2 -


http://files.shareholder.com/downloads/ABEA-4ITCYZ/1877348381x0x561958/968184e3-1d80-40b0-b850-9516be738d22/PMX-30063%20Phase%202%20Full%20DataWebcast%204-23-12%20(final).pdf


Misc discussion of the Polymedix Phase 2 results -


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=75515171


(continued)







Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up